Search - tctmd.com

Displaying 401 - 420 of 584

Sort: Relevancy | Date

News Conference News ACC 2019

Modest LDL Cholesterol Reduction With Bempedoic Acid in Among High-Risk Patients: CLEAR Wisdom

Michael O'Riordan

March 20, 2019

News Daily News

‘Striking’ Improvements in Acute MI Care Over Past 20 Years, Report Shows

Michael O'Riordan

March 19, 2019

News Conference News ACC 2019

New Primary Prevention Guidelines Axe Aspirin, Pushing Routine Check-ins, Social Clues Instead

Michael O'Riordan

March 17, 2019

News Daily News

Bempedoic Acid Boosts LDL Cholesterol-Lowering in Statin-Treated CVD Patients: CLEAR Harmony

Michael O'Riordan

March 15, 2019

News Daily News

Rising Inflammatory Tides: Increasing CRP Levels After ACS Tied to Greater CVD Risks

Michael O'Riordan

March 08, 2019

News Daily News

Signal of Aortic Stenosis Risk With Celecoxib

Michael O'Riordan

March 05, 2019

News Daily News

ISCHEMIA Patients: High Rates of Severe-to-Moderate Ischemia, Multivessel CAD

Michael O'Riordan

March 01, 2019

News Daily News

New Equations Help ID Patients at Low Risk for Bleeding With Aspirin

Michael O'Riordan

February 26, 2019

News Daily News

Age Shouldn’t Be a Barrier to Statin Therapy, Meta-analysis Suggests

Michael O'Riordan

February 08, 2019

News Features

Hopes Fade for a CV Indication for Canakinumab: What’s Next for the Inflammatory Hypothesis?

Michael O'Riordan

February 01, 2019

News Daily News

AHA Warns of Stagnating CVD Gains, Barriers to Access, and Dismal Drug Pipeline

Michael O'Riordan

January 29, 2019

News Features

Top News in Prevention: 2018

Michael O'Riordan

December 28, 2018

News Daily News

Now You See It: Imaging Helps Lower CVD Risk Burden in Primary Prevention

Michael O'Riordan

December 10, 2018

News Daily News

Benefits of Statins Only Exceed Harms at Higher 10-Year Risk Thresholds, Study Suggests

Michael O'Riordan

December 03, 2018

News Daily News

Aspirin Should Play Limited Role in Primary Prevention: Review

Michael O'Riordan

November 27, 2018

News Daily News

Angina Without Obstructive Stenosis: No Longer a ‘Black Box’ Mystery, Say Experts

Michael O'Riordan

November 23, 2018

News Conference News AHA 2018

EMPA-HEART Offers Mechanistic Clues for Empagliflozin’s Cardiac Benefits

Michael O'Riordan

November 16, 2018

News Conference News AHA 2018

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

Michael O'Riordan

November 15, 2018

News Conference News AHA 2018

Methotrexate, an Anti-inflammatory, Fails to Lower Risk of Cardiovascular Events: CIRT

Michael O'Riordan

November 10, 2018

News Conference News AHA 2018

New Cholesterol Guidelines Make Room for Non-Statin Therapy and CAC Screening

Michael O'Riordan

November 10, 2018

Advertisement

Modest LDL Cholesterol Reduction With Bempedoic Acid in Among High-Risk Patients: CLEAR Wisdom

‘Striking’ Improvements in Acute MI Care Over Past 20 Years, Report Shows

New Primary Prevention Guidelines Axe Aspirin, Pushing Routine Check-ins, Social Clues Instead

Bempedoic Acid Boosts LDL Cholesterol-Lowering in Statin-Treated CVD Patients: CLEAR Harmony

Rising Inflammatory Tides: Increasing CRP Levels After ACS Tied to Greater CVD Risks

Signal of Aortic Stenosis Risk With Celecoxib

ISCHEMIA Patients: High Rates of Severe-to-Moderate Ischemia, Multivessel CAD

New Equations Help ID Patients at Low Risk for Bleeding With Aspirin

Age Shouldn’t Be a Barrier to Statin Therapy, Meta-analysis Suggests

Hopes Fade for a CV Indication for Canakinumab: What’s Next for the Inflammatory Hypothesis?

AHA Warns of Stagnating CVD Gains, Barriers to Access, and Dismal Drug Pipeline

Top News in Prevention: 2018

Now You See It: Imaging Helps Lower CVD Risk Burden in Primary Prevention

Benefits of Statins Only Exceed Harms at Higher 10-Year Risk Thresholds, Study Suggests

Aspirin Should Play Limited Role in Primary Prevention: Review

Angina Without Obstructive Stenosis: No Longer a ‘Black Box’ Mystery, Say Experts

EMPA-HEART Offers Mechanistic Clues for Empagliflozin’s Cardiac Benefits

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

Methotrexate, an Anti-inflammatory, Fails to Lower Risk of Cardiovascular Events: CIRT

New Cholesterol Guidelines Make Room for Non-Statin Therapy and CAC Screening

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content